Trial Profile
Pharmacokinetic and Pharmacodynamic Studies of Efficacy, Tolerability and Safety of Higher Dosage Rifapentine for Treatment of Tuberculosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2021
Price :
$35
*
At a glance
- Drugs Rifapentine (Primary) ; Rifampicin
- Indications Pulmonary tuberculosis; Tuberculosis
- Focus Biomarker; Pharmacogenomic; Pharmacokinetics
- 12 Jul 2021 Results of a longitudinal model-based biomarker analysis of exposure response of data pooled from 2 clinical trials (Study 29 and study 29X) published in the Antimicrobial Agents and Chemotherapy
- 16 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jul 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.